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his joint position statement represents the combined
fforts of four professional societies (Society of Thoracic
urgeons [STS], American Association for Thoracic Sur-
ery [AATS], American College of Cardiology [ACC], and
ociety for Cardiovascular Angiography and Interventions
SCAI]), two government agencies (the U.S. Food and
rug Administration [FDA] and the Centers for Medicare
nd Medicaid Services [CMS]), and numerous industry
epresentatives to assess the foreseeable directions of a class
f emerging technologies being developed to enable the
ercutaneous treatment of cardiac valve dysfunction. Percu-
aneous heart valve technology (PHVT) is a less invasive
eans of treating valvular heart disease. The goals of the
nterdisciplinary group have been to establish cooperation,
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ROCESS
n April 22, 2004, the STS/AATS Committee/Workforce
or the Assessment of New Technology (Appendix 1)
rganized a workshop on PHVT. Included were represen-
atives from the STS, the AATS, the ACC, and SCAI.
lso in attendance were representatives from the FDA’s
ivision of Cardiovascular Devices, Circulatory Support
nd Prosthetic Devices Branch, CMS, and industry repre-
entatives (Appendix 2). Clinical aspects of PHVT were
nitially addressed in small groups with representatives from
ach of the constituencies followed by a summary report and
iscussion amongst the entire group. All participants of the
orkshop and writing group members completed a disclo-
ure questionnaire documenting all outside relationships
hat might be perceived as real or potential conflicts of
nterest (1). Current crucial issues addressed were: 1) trial
esign, 2) control groups, 3) end points for assessment, 4)
ate of technological change, 5) institutional and investiga-
or requirements, and 6) safety. Consideration of these
ssues is undertaken with the acknowledgement that for
ost patients with heart valve disease, open cardiac surgical
rocedures provide an established form of treatment.
ACKGROUND
or decades, percutaneous interventional therapy has been
n option for patients with pulmonic (2–4), mitral (5,6),
nd aortic valvular disease (7,8). For selected patients with
ulmonic or mitral stenosis, percutaneous valvuloplasty is
he treatment of choice (9,10). For patients with calcific
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has been used as a bridge to aortic valve replacement a
noted by the current ACC/American Heart Association
(AHA) guidelines (13). Hospital mortality for BAV varie
from 3.5% to 13.5%, and as many as 25% of the patient
have at least one serious complication (14). The durability o
BAV is limited. Therefore, open aortic valve replacemen
remains the definitive therapy for aortic stenosis in patient
who are viable candidates for surgery.
Currently, multiple new concepts for the percutaneou
treatment of valvular heart disease are under evaluation in a
variety of stages from bench testing to early clinical trial
(15). Most involve either mitral valve repair via annular o
leaflet manipulation, or percutaneous valve insertion fo
pulmonic or aortic valve disease. Using a stent-based valve
(16,17), percutaneous pulmonary valve insertion has been
successfully carried out in more than 60 cases, primarily
outside the U.S., usually for the treatment of condui
stenosis (18). However, late follow-up is limited and future
trials will need to focus on the issues of patient selection
with degenerated conduits, durability and the inability o
the device to grow. Although percutaneous aortic valve
insertion has been carried out on a compassionate use fo
extremely high-risk patients (19,20), significant para-
valvular regurgitation and early mortality characterize the
experience thus far (21). Currently, there are no approved
percutaneous aortic valve devices in the U.S.
The goal of the following discussion is to provide a
framework for clinical research directed at further testing o
PHVT.
GENERAL GUIDELINES REGARDING
CLINICAL TRIAL DESIGN FOR PHVT
The testing of new medical technology usually begins with
bench testing (in vitro) and in vivo animal testing, followed
by clinical investigation. Initial clinical investigation begin
with a feasibility study: a small, unblinded, and uncontrolled
trial designed to test safety. Following the feasibility trials, a
larger, prospective, controlled trial is performed to evaluate
both safety and efficacy (Pivotal trial). The most rigorou
design for establishing the safety and effectiveness of new
technology is the controlled, randomized trial. It is the
consensus of the participants of the Workshop that no
adequate historical controls exists for the evaluation o
PHVT sufficient to eliminate the influence of confounding
variables. Therefore, randomized controlled trials are nec-
essary to evaluate safety and efficacy properly for these
devices.
At each institution participating in clinical trials, the
study team should include at least an interventionalist, a
cardiac surgeon, a non-interventional clinical investigato
charged with monitoring patient welfare, and an echocar-
diographer. All members of the study team should be
charged with ensuring proper patient selection to achieve
safety and objectivity. Furthermore, such collaborative in-teraction will aid trial completion and, it is hoped, lead to
improvement in device placement, function, and assess-
ment.
Use of PHVT requires skill sets independent of the
operator’s base discipline, and specific training should be
required before engaging in any percutaneous valve proce-
dure. Those individuals eligible for the procedural training
should be confined to experienced interventionalists and
surgeons. Feasibility studies in adults should be restricted to
a small number of high-volume cardiology and cardiac
surgery programs where at least 100 to 150 surgical valve
operations per year are performed (22). Participating cardiac
surgeons should perform a minimum of 40 to 50 valve
repairs or replacements annually (23). In addition, the
surgeon’s valve experience should be specific for the device
under consideration (i.e., a surgeon with a large volume o
aortic valve replacement and minimal mitral valve repai
would only qualify for an aortic device study). Although
most interventionalists are likely to be cardiologists, o
rarely interventional radiologists, surgeons with appropriate
training in percutaneous procedures may directly partici-
pate, in addition to providing patient selection, guidance
and back-up services. Interventionalists should perform a
least 100 percutaneous procedures each year, and have
experience with the catheter-based techniques required fo
PHVT (e.g., trans-septal and/or coronary sinus acces
techniques) and with the assessment and management o
valvular heart disease (24–26). Clinical trials should also be
limited to centers with a proven track record of close
collaboration between the aforementioned disciplines and
experience in trials.
A major problem with all new devices is how to evaluate
a first-generation product against the established “gold
standard,” in this case the open cardiac surgical procedure
How should a new device that avoids cardiac surgery bu
perhaps is less effective—especially initially—be best eval-
uated? At the design stage of a clinical trial it is essential to
state clearly the purpose of the study and the specific
hypothesis to be evaluated (27). Randomized controlled tria
designs can be broadly viewed as evaluating the superiority
or non-inferiority (clinical equivalence) of the test arm with
regard to effectiveness. Critical differences exist between
these two approaches, which affect sample size, study
feasibility, and credibility of conclusions (28). It is impor-
tant to point out that it is statistically, and practically
impossible to demonstrate equivalence between two treat-
ment arms, as some differences are always likely to exist
Therefore, a “clinically acceptable” difference (“delta”) be-
tween the two treatment arms must be specified at the
outset and the null hypothesis constructed such that it
rejection supports the claim of non-inferiority (Table 1).
Sample size estimation would be most appropriately
determined by power calculations for the specific end poin
and study results published in the literature. Study end
points should be chosen that can be assessed objectively by:
1) creating clear criteria for the outcome, 2) collecting the
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laboratories, blinded to the treatment assignment, adjudi-
cate the cases whenever possible. Meaningful outcome
measurements could include components such as death
myocardial infarction, need for surgical repair (including the
need for valve replacement when repair was the preoperative
intent), stroke or embolic events, hemodynamic deteriora-
tion, ejection fraction, measures of reverse remodeling
valvular regurgitation, endocarditis, hemolysis, and func-
tional testing. Although the timing of end point measure-
ments was discussed at the Workshop, the consensus wa
that it is too early in PHVT development to answer thi
question.
Finally, in any trial designed to evaluate an intervention
“crossovers” are likely to occur. Crossover patients can be
analyzed using several methods, including “intent to treat,
“as treated,” and “per protocol” (29,30). In addition, a large
amount of missing end point data can make interpretation
of trial results difficult and threaten the success of the trial
Every effort should be made to collect all data specified in
the trial. Additionally, the importance of a knowledgeable
and active Data Safety and Monitoring Board cannot be
overemphasized. This board should be independent of the
investigators, of the company sponsoring the trial, and o
any contracted data analysis organizations involved in the
trial.
PERCUTANEOUS MITRAL VALVE
REPAIR (PMVR) FOR MITRAL REGURGITATION
The pathophysiologic triad describing mitral regurgitation
(MR) is composed of etiology (cause of the disease), valve
lesions (resulting from the disease), and valve dysfunction
(resulting from the lesion) (31). These distinctions are
relevant because long-term prognosis depends on etiology
whereas surgical treatment strategy—and future PMVR—
depends on valve dysfunctions and lesions. Mild to moder-
ate MR is seen in approximately 20% of the genera
population (32,33). The most common causes of MR in
Western countries are degenerative, ischemic, and dilated
cardiomyopathy (34).
The STS National Adult Cardiac Surgery Database 2003
notes a countrywide mortality for first time elective mitra
Table 1. Randomized Controlled Trial Designs
Trial Design Type
Null Hypothesis for
Effectiveness
Alternate
Hypothesis for
Effectiveness
Superiority Treatment A success
rate  treatment B
rate
Treatment A success
rate  treatment B
rate
Non-inferiority Treatment A success
rate  treatment B
rate  “delta”
Treatment A success
rate  treatment B
rate  “delta”valve repair of 2.5% (males) to 3.9% (females), and for
mitral valve surgery combined with coronary artery bypassthese figures are 6.1% (males) to 12.2% (females), respec-
tively (35). Patients undergoing reoperation are also a
increased risk (36). Mitral valve repair is considered superio
to mitral valve replacement because of lower operative
mortality, improved late survival, a reduced risk of endocar-
ditis, fewer thromboembolic complications, and better pres-
ervation of left ventricular function (37–42). However, the
majority of mitral valve operations done in the U.S. in 2003
remained mitral valve replacement (43). Individual surgeon
experience remains the key factor in predicting the likeli-
hood of mitral valve repair or replacement for any given
patient.
To discuss patient selection for PMVR for MR and to
consider comparative outcomes with surgical approaches, i
is possible to consider two classifications: one focusing on
etiology and the other on leaflet dysfunction, realizing tha
both can influence patient outcome. For the purposes of thi
discussion, we will focus on leaflet dysfunction as opposed to
etiology (33). This classification is based on the opening and
closing motions of the mitral leaflets. Patients with type I
dysfunction have normal leaflet motion. Mitral regurgita-
tion in these patients is due to annular dilatation or leafle
perforation. There is increased leaflet motion in patient
with type II dysfunction with the free edge of the leafle
overriding the plane of the annulus during systole (leafle
prolapse). The most common lesions responsible for type I
dysfunction are chordal elongation or rupture and papillary
muscle elongation or rupture. Patients with type IIIa dys-
function have restricted leaflet motion during both diastole
and systole. The most common lesions are leaflet thicken-
ing/retraction, chordal thickening/shortening or fusion, and
commissural fusion. The mechanism of MR in type IIIb
dysfunction is restricted leaflet motion during systole: lef
ventricular enlargement with apical papillary muscle dis-
placement due to ischemic or idiopathic cardiomyopathy
causes this type of valve dysfunction.
Currently, there are two concepts for percutaneous mitra
valve repair: 1) partial mitral annuloplasty by device place-
ment in the coronary sinus to reduce the circumference o
the posterior mitral annulus; and 2) anterior and posterio
leaflet attachment using an edge-to-edge clip or suture
(44–46). Posterior annuloplasty faces multiple anatomic
challenges including dilation of the trigone-to-trigone area
(47,48), leaflet tethering by papillary muscle displacemen
(49), mitral annular calcification, inability to fix the annu-
loplasty to the fibrous trigones (50), and the potential fo
compromise of the circumflex coronary artery. The edge-
to-edge repair concept has been used in surgically treated
patients, but the best results have been obtained when
combined with an annuloplasty (51). The results of edge-
to-edge repair have been suboptimal in patients with re-
stricted leaflet motion (type III dysfunction), including a
recent surgical series where it was used in combination with
a posterior annuloplasty in patients with ischemic regurgi-
tation (52).
A feasibility study designed to evaluate PMVR with
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patients with severe symptomatic MR caused by annula
dilation with normal leaflet motion (type I dysfunction) o
by restricted leaflet motion (type IIIb dysfunction), or by a
combination of these two mechanisms. A feasibility study to
evaluate PMVR with leaflet edge-to-edge repair should
consist of 20 to 30 patients with excessive leaflet motion
(type II dysfunction).
These studies will have safety as the primary end poin
and will assess adverse events including residual (equal o
worse) MR, myocardial infarction, stroke, tamponade, cor-
onary artery injury, death, and leaflet damage compromising
subsequent mitral valve repair. The secondary end points o
the study will include quantitative echocardiographic assess-
ment of MR diminution, left ventricular function, and
symptom status. The design of Pivotal trials will need to
await safety and durability data from the feasibility study
but will include: 1) comparison of PMVR to open surgica
mitral valve repair in patients with types I, II, and IIIb
dysfunction; or 2) comparison of PMVR to optimal medica
therapy (53) in non-surgical candidates with either end-stage
cardiomyopathy and type IIIb severe MR or elderly patient
with significant comorbidities and type II dysfunction.
PERCUTANEOUS AORTIC VALVE REPLACEMENT
(PAVR)
Aortic valve replacement is the most common heart valve
operation. Aortic stenosis (AS) affects from 2% to 7% o
individuals older than 65 years in the U.S., a prevalence tha
will continue to increase as more people live to older age
(54,55). Aortic stenosis is consistently progressive (56–59)
and because it occurs in an elderly age group it is often
associated with comorbid risk factors and previous bypas
surgery (60). The goals of therapy for patients with AS
include both improvement of symptoms and prolongation
of life (61). Percutaneous strategies for the treatment of AS
began with percutaneous balloon valvuloplasty, but data
from single-center studies and the multicenter Nationa
Heart, Lung, and Blood Institute (NHLBI) registry noted
only a modest improvement in early hemodynamics, a
substantial incidence of peripheral vascular complications, a
30-day mortality of 7%, and a high incidence of restenosi
within 6 months (7,62).
The disappointing results of BAV have led to investiga-
tion of the possibility of percutaneous placement of pros-
thetic aortic valves. Such devices have been used clinically in
a small number of cases in high-risk patients (63). A
feasibility study designed to evaluate PAVR might consis
of 20 to 30 patients with severe symptomatic AS (aortic
valve area 0.70 cm2), or severe aortic valve regurgitation
(AR). Initial feasibility trials have treated only AS patient
because AR treatment is more problematic for the first
generation of PAVR devices. Therefore, it is envisioned thatfeasibility trials will initially enroll only patients with severe
AS.
In addition, differences in the age and comorbidity
between patients with AS and AR dictate each study
population be fairly pure, with a cohort of one or the othe
but not a mixture. These initial patients should be judged to
be at extremely high operative risk as calculated by an
established risk scoring system (64–67). Selection of a risk
scoring system as well as the definition of inoperability
should be clearly defined in the protocol. Such inoperability
will almost always be caused by non-cardiac morbid condi-
tions. In such a feasibility trial it is not acceptable to use
such devices for patients who simply refuse open surgery on
the basis of personal preference. Study end points wil
include death, stroke, myocardial infarction, para-prosthetic
leak, device migration, symptom status, angiographic gra-
dient, and rehospitalization. Pivotal trials will depend upon
the safety data from the feasibility trial, and a variety o
control groups may be possible including patients having
balloon valvuloplasty and high-risk open surgery.
MINIMALLY INVASIVE VALVE SURGERY
The procedural goal of PHVT is to reliably repair or replace
dysfunctional heart valves percutaneously and without the
need for cardiopulmonary bypass (CPB). An alternate
approach has been to repair or replace valves off-pump
through small incisions, thereby simplifying device delivery
Concepts along these lines include anterior and posterio
pads connected by a subvalvular cord designed to draw the
posterior leaflet and annulus of the mitral valve toward the
anterior leaflet (68); a transatrial off-pump edge-to-edge
mitral valve repair (69); and off-pump AR antegrade
through the ascending aorta or retrograde through the lef
ventricular apex (70). The minimally invasive surgical ap-
proach is an avenue of treating heart valve disease that no
only has benefit on its own merit but also supports devel-
opment of PHVT.
REGULATORY CONSIDERATIONS
At this Workshop, the general considerations of the FDA
as expressed by Bram Zuckerman, Director of Cardiovas-
cular Devices, Office of Device Evaluation (ODE), Cente
for Devices and Radiologic Health, were as follows. Percu-
taneous heart valve systems are considered class III devices
they will be reviewed as pre-market approval (PMA) appli-
cations (71) and, as such, controlled, randomized clinica
trials will be the gold standard for meeting FDA require-
ments. Industry or independent study investigators should
solicit the assistance and guidance of the FDA before
designing any clinical trial for PHVT (72). Post-market
approval studies may be required.
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Clinical Development of Percutaneous Heart Valve Technology May 3, 2005:1554–60SUMMARY
Although percutaneous devices for the repair or replacemen
of heart valves appear promising, they are clearly in an early
stage of development. Many critical questions remain un-
answered, including the durability of these devices and the
potential adverse effects they may have on subsequent hear
valve surgery. Therefore, one cannot justify the use of these
experimental technologies in patients for whom published
guideline indications do not exist or in situations of pro-
phylactic therapy until data on safety and effectiveness are
gathered from well-designed clinical trials. Study candidate
should consist of symptomatic patients in whom long-term
survival is already severely compromised. Such a strategy
would allow the collection of mid-term device durability
data while providing much needed clinically relevant safety
and effectiveness data.
Prospective, randomized, clinical trials provide the mos
reliable evidence of the effectiveness of the treatment
Without such trials, ineffective treatments (or worse, harm-
ful treatments) may be accepted in medical practice. Ou
collective enthusiasm for new, less-invasive cardiovascula
approaches should not divert us from the importance o
evaluating these devices in the context of a controlled
clinical trial environment. Success of these clinical trial
ultimately depends upon a sincere commitment to collabo-
ration between cardiology and cardiac surgery.
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